It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CDNA’s FA Score shows that 1 FA rating(s) are green whileZOM’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CDNA’s TA Score shows that 4 TA indicator(s) are bullish while ZOM’s TA Score has 2 bullish TA indicator(s).
CDNA (@Medical Specialties) experienced а +0.39% price change this week, while ZOM (@Medical Specialties) price change was -2.52% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.69%. For the same industry, the average monthly price growth was -0.14%, and the average quarterly price growth was -1.28%.
CDNA is expected to report earnings on Feb 26, 2025.
ZOM is expected to report earnings on Mar 04, 2025.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
CDNA | ZOM | CDNA / ZOM | |
Capitalization | 548M | 137M | 400% |
EBITDA | -84.92M | -11.94M | 712% |
Gain YTD | 91.500 | -40.060 | -228% |
P/E Ratio | N/A | N/A | - |
Revenue | 280M | 24M | 1,167% |
Total Cash | 235M | 106M | 222% |
Total Debt | 34.2M | 1.75M | 1,952% |
CDNA | ZOM | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 28 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 94 | |
PRICE GROWTH RATING 1..100 | 36 | 82 | |
P/E GROWTH RATING 1..100 | 1 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZOM's Valuation (28) in the Pharmaceuticals Major industry is significantly better than the same rating for CDNA (100) in the Medical Specialties industry. This means that ZOM’s stock grew significantly faster than CDNA’s over the last 12 months.
ZOM's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CDNA (100) in the Medical Specialties industry. This means that ZOM’s stock grew similarly to CDNA’s over the last 12 months.
ZOM's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as CDNA (96) in the Medical Specialties industry. This means that ZOM’s stock grew similarly to CDNA’s over the last 12 months.
CDNA's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for ZOM (82) in the Pharmaceuticals Major industry. This means that CDNA’s stock grew somewhat faster than ZOM’s over the last 12 months.
CDNA's P/E Growth Rating (1) in the Medical Specialties industry is significantly better than the same rating for ZOM (100) in the Pharmaceuticals Major industry. This means that CDNA’s stock grew significantly faster than ZOM’s over the last 12 months.
CDNA | ZOM | |
---|---|---|
RSI ODDS (%) | 2 days ago90% | N/A |
Stochastic ODDS (%) | 2 days ago87% | 2 days ago80% |
Momentum ODDS (%) | 2 days ago85% | 2 days ago87% |
MACD ODDS (%) | 2 days ago89% | 2 days ago84% |
TrendWeek ODDS (%) | 2 days ago86% | 2 days ago85% |
TrendMonth ODDS (%) | 2 days ago87% | 2 days ago82% |
Advances ODDS (%) | 2 days ago84% | 9 days ago83% |
Declines ODDS (%) | 12 days ago85% | 6 days ago84% |
BollingerBands ODDS (%) | 2 days ago82% | N/A |
Aroon ODDS (%) | 2 days ago86% | 2 days ago81% |
A.I.dvisor indicates that over the last year, ZOM has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOM jumps, then SNDL could also see price increases.
Ticker / NAME | Correlation To ZOM | 1D Price Change % | ||
---|---|---|---|---|
ZOM | 100% | -0.17% | ||
SNDL - ZOM | 38% Loosely correlated | +2.37% | ||
CDNA - ZOM | 30% Poorly correlated | +1.50% | ||
OSUR - ZOM | 30% Poorly correlated | +0.96% | ||
EBS - ZOM | 29% Poorly correlated | -3.84% | ||
ARAY - ZOM | 29% Poorly correlated | +2.29% | ||
More |